Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Iogenetics LLC is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. CUNNINGCHEN, KATHLEEN MARY is identified as the busiest examiner for the portfolio, currently holding 1 pending office action. The distribution of 2 pending office actions total across 2 distinct examiners indicates that the company's prosecution is not concentrated under a single individual.
Each of the 2 distinct art units represents a different technical focus within the biotechnology sector. This structure requires the applicant to manage two separate prosecution tracks, as the busiest examiner, CUNNINGCHEN, KATHLEEN MARY, only handles half of the current pending workload. This diversity of examiners and art units suggests that the company's intellectual property strategy involves navigating a variety of examiner perspectives. Practitioners must ensure consistency in technical arguments across both art units to maintain a cohesive portfolio. The presence of multiple examiners in the Biotechnology & Pharmaceuticals area indicates that the company is pursuing diverse research paths. Successfully managing these separate interactions will be essential for the company's overall patent strategy. This decentralized approach requires careful coordination to ensure that all pending matters reach a favorable conclusion.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| KALLAL, ROBERT JAMES | 1 | 60.0% | +32.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18170396 | EPITOPE MIMICS | KALLAL, ROBERT JAMES | 16d |
| 18256241 | BYSTANDER PROTEIN VACCINES | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18170396 | EPITOPE MIMICS | KALLAL, ROBERT JAMES | 16d |
| 18256241 | BYSTANDER PROTEIN VACCINES | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256241 | BYSTANDER PROTEIN VACCINES | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103§112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18170396 | EPITOPE MIMICS | KALLAL, ROBERT JAMES | 1685 | §101§112 | Non-Final OA | 16d | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial